-
公开(公告)号：WO2017067964A1
公开(公告)日：2017-04-27
申请号：PCT/EP2016/075048
申请日：2016-10-19
Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
Inventor： FERON, Christiane Marie-Paule Simone Jeanne , KEMMLER, Stefan Jochen , KOWARIK, Michael Thomas , QUEBATTE, Julien Laurent
IPC: A61K39/104 , A61K39/385 , C07K14/21 , A61P31/04 , A61K39/00
CPC classification number: A61K39/104 , A61K39/385 , A61K45/06 , A61K47/6415 , A61K47/646 , A61K2039/6037 , A61K2039/6068 , A61K2039/6087 , A61K2039/64 , C07K14/21 , C07K2319/00 , Y02A50/47
Abstract: The present invention discloses a conjugate comprising an antigen (for example a saccharide antigen) covalently linked to a Pseudomonas aeruginosa PcrV carrier protein comprising an amino acid sequence which is at least 80% identical to the sequence of SEQ ID NO:1-4, wherein the antigen is linked (either directly or through a linker) to an amino acid residue of the P. aeruginosa PcrV carrier protein. The invention also discloses Pseudomonas aeruginosa PcrV proteins that contain glycosylation site consensus sequences.
Abstract translation: 本发明公开了包含与铜绿假单胞菌PcrV载体蛋白共价连接的抗原（例如糖抗原）的缀合物，所述抗原包含与SEQ ID NO：1的序列至少80％相同的氨基酸序列 其中抗原连接（直接或通过接头）至铜绿假单胞菌PcrV载体蛋白的氨基酸残基。 本发明还公开了含有糖基化位点共有序列的铜绿假单胞菌PcrV蛋白质。
-
公开(公告)号：WO2017067962A1
公开(公告)日：2017-04-27
申请号：PCT/EP2016/075045
申请日：2016-10-19
Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
Inventor： BERTAUD, Elisabeth Marie Monique , BIEMANS, Ralph Leon , MONIOTTE, Nicolas Jean Benoit , STRODIOT, Laurent Bernard Jean
CPC classification number: A61K39/092 , A61K47/6415 , A61K47/646 , A61K2039/6087 , A61K2039/62 , A61K2039/70
Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. M w ) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.
Abstract translation: 本发明属于肺炎球菌荚膜糖类缀合物疫苗领域。 具体而言，本发明涉及大小的肺炎链球菌血清型6A荚膜多糖，特别是肺炎链球菌血清型6A荚膜多糖的平均大小（例如M w）的肺炎链球菌血清型6A荚膜多糖在100 -1000kDa，适当地与载体蛋白缀合。
-
3.发明申请CYTOKINE-CHITOSAN BIOCONJUGATES AND METHODS OF USING THE SAME 审中-公开细胞因子-CHITOSAN BIOCONJUGATES及其使用方法
公开(公告)号：WO2015184445A8
公开(公告)日：2017-04-06
申请号：PCT/US2015033541
申请日：2015-06-01
Applicant: UNIV ARKANSAS
Inventor： ZAHAROFF DAVID A , THALLAPURANAM SURESH KUMAR , JAYANTHI SRINIVAS , KOPPOLU BHANU PRASANTH , SMITH SEAN C
IPC: A01N43/04 , A61K31/715
CPC classification number: A61K47/4823 , A61K38/208 , A61K39/39 , A61K45/06 , A61K47/61 , A61K47/62 , A61K2039/6087
Abstract: Compositions including chitosan covalently linked to a cytokine or growth factor are provided herein. The compositions can be used to produce pharmaceutical compositions and can be used in methods of treating a variety of diseases or disorders. The compositions are especially suitable for localized delivery and may allow for intratumoral delivery and treatment of cancers or stimulation of an immune response to a co-administered antigen.
Abstract translation: 本文提供了包含与细胞因子或生长因子共价连接的壳聚糖的组合物。 该组合物可用于制备药物组合物，并可用于治疗各种疾病或病症的方法。 组合物特别适用于局部递送，并且可以允许肿瘤内递送和治疗癌症或刺激对共同给予的抗原的免疫应答。
-
4.发明申请METHODS AND COMPOSITIONS FOR IMMUNE PROTECTION AGAINST EXTRA-INTESTINAL PATHOGENIC E. COLI 审中-公开用于免疫保护的方法和组合物对非特异性致病性大肠杆菌
公开(公告)号：WO2017035181A1
公开(公告)日：2017-03-02
申请号：PCT/US2016/048278
申请日：2016-08-24
Applicant: GLYCOVAXYN AG , JANSSEN PHARMACEUTICALS, INC.
Inventor： POOLMAN, Jan, Theunis , JACQUEMYN, Bert , ABBANAT, Darren, Robert , YON, Patricia, Ibarra , HERMANS, Peter, Wilhelmus, Maria , KOWARIK, Michael, Thomas , WETTER, Michael, Lukas , KEMMLER, Stefan, Jochen , HAUPTLE, Micha, Andres , GAMBILLARA, Veronica , MALLY, Manuela
IPC: A61K39/02 , C08B37/00 , A61K39/00 , A61K39/108
CPC classification number: A61K39/0258 , A61K47/6415 , A61K47/646 , A61K2039/545 , A61K2039/55583 , A61K2039/6037 , A61K2039/6087 , A61K2039/70 , C08B37/0063 , Y02A50/474
Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.
Abstract translation: 描述了诱导针对肠外致病性大肠杆菌（ExPEC）的免疫应答的组合物和方法，从而为与ExPEC相关的疾病提供免疫保护。 具体地，描述了使用与铜绿假单胞菌（EPA）载体蛋白的解毒外毒素A共价结合的大肠杆菌多糖抗原O25B，O1A，O2和O6A的缀合物的组合物和方法作为用于预防引起的侵袭性ExPEC疾病的疫苗 通过ExPEC血清型O1A，O2，O6A和O25B。
-
5.发明申请
公开(公告)号：WO2015179270A3
公开(公告)日：2016-01-07
申请号：PCT/US2015031325
申请日：2015-05-18
Applicant: UNIV TEXAS
Inventor： TRENT M STEPHEN , BOLL JOSEPH M
CPC classification number: A61K39/145 , A61K39/107 , A61K39/12 , A61K2039/522 , A61K2039/5252 , A61K2039/55572 , A61K2039/55583 , A61K2039/575 , A61K2039/6006 , A61K2039/6087 , A61K2039/62 , A61K2039/70 , C07K14/005 , C07K14/195 , C07K2319/03 , C07K2319/21 , C07K2319/42 , C07K2319/91 , C12N7/00 , C12N9/1081 , C12N15/52 , C12N2760/16022 , C12N2760/16034 , C12N2760/16071 , C12N2760/16134 , C12Y204/99019
Abstract: Engineered bacteria are provided that produce modified lipid A and a polypeptide or polysaccharide antigens. In some aspects, immunogenic compositions are provided comprising a modified a lipid A and a polypeptide or polysaccharide antigen.
Abstract translation: 提供了产生经修饰的脂质A和多肽或多糖抗原的工程细菌。 在一些方面，提供包含修饰的脂质A和多肽或多糖抗原的免疫原性组合物。
-
Patent Agency Ranking
公开(公告)号：WO2015050158A1
公开(公告)日：2015-04-09
申请号：PCT/JP2014/076286
申请日：2014-10-01
Applicant: 国立大学法人三重大学 , 国立大学法人京都大学
CPC classification number: A61K39/0011 , A61K9/0019 , A61K39/015 , A61K39/12 , A61K47/36 , A61K2039/55583 , A61K2039/6087 , C12N2710/16122 , C12N2710/16134
Abstract: 複数個のエピトープを有する長鎖ペプチド抗原おいて、各エピトープの抗原提示を有効に誘導するエピトープ間配列を提供すること。複数個のエピトープを有する長鎖ペプチド抗原を備えたワクチンにおいて、各エピトープ間配列は、２個～１０個の連続するチロシン、２個～１０個の連続するスレオニン、２個～１０個の連続するアラニン、２個～１０個の連続するヒスチジン、２個～１０個の連続するグルタミン及び２個～１０個の連続するアスパラギンからなる群から選択される一つであることを特徴とするワクチンによって達成される。このワクチンは、抗がんワクチン、抗菌ワクチン及び抗ウイルスワクチンからなる群から選択される一つであることが好ましい。また、ワクチンは、ペプチドワクチン、ＤＮＡワクチン、ｍＲＮＡワクチン、樹状細胞ワクチンからなる群から選択される少なくとも一つのものであることが好ましい。
Abstract translation: 本发明的目的是提供一种有效诱导具有多个表位的长链肽抗原中每个表位的抗原呈递的插入片段序列。 为此，提供了包含具有多个表位的长链肽抗原的疫苗，所述疫苗的特征在于，各个表位之间的序列是选自2-10个连续酪氨酸残基，2 -10个连续的苏氨酸残基，2-10个连续的丙氨酸残基，2-10个连续的组氨酸残基，2-10个连续的谷氨酰胺残基和2-10个连续的天冬酰胺残基。 优选该疫苗是选自抗癌疫苗，抗菌疫苗和抗病毒疫苗的疫苗。 还优选该疫苗是选自肽疫苗，DNA疫苗，mRNA疫苗和树突细胞疫苗中的至少一种疫苗。
-
公开(公告)号：WO2014008406A2
公开(公告)日：2014-01-09
申请号：PCT/US2013/049337
申请日：2013-07-03
Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
Inventor： WATNICK, Paula, I.
IPC: A61K39/02
CPC classification number: A61K39/107 , A61K38/47 , A61K39/02 , A61K47/48776 , A61K47/6901 , A61K2039/52 , A61K2039/55594 , A61K2039/6006 , A61K2039/6087 , A61K2039/627 , C12Y302/01014 , Y02A50/472
Abstract: Some aspects of this disclosure provide engineered exopolysaccharide-associated proteins, engineered bacteria expressing such proteins, and engineered biofilms comprising such proteins. Some aspects of this disclosure provide methods for engineering exopolysaccharide-associated proteins, and for the generation of engineered bacteria and biofilms expressing or comprising such proteins. Some aspects of this disclosure provide compositions and methods useful for the generation of vaccines and the vaccination of subjects, for delivering molecules of interest to a target site, for example, a surface, for purification of molecules of interest, for example, from bioreactors comprising engineered bacteria as provided herein, and for bioremediation applications, such as the cleanup of environmental pollutants.
Abstract translation: 本公开的一些方面提供了工程化的外多糖结合蛋白，表达此类蛋白的工程化细菌和包含此类蛋白的工程化生物膜。 本公开的一些方面提供了用于工程化外多糖相关蛋白质以及用于产生表达或包含这种蛋白质的工程细菌和生物膜的方法。 本公开的一些方面提供用于产生疫苗和受试者的疫苗接种的组合物和方法，所述组合物和方法用于将感兴趣的分子递送至目标位点例如表面以用于纯化感兴趣的分子，例如来自生物反应器的生物反应器， 如本文提供的工程细菌，以及生物修复应用，例如环境污染物的净化。
-
公开(公告)号：WO2012118857A2
公开(公告)日：2012-09-07
申请号：PCT/US2012027021
申请日：2012-02-28
Applicant: UNIV CENTRAL OKLAHOMA , CHEN WEI R
Inventor： CHEN WEI R
CPC classification number: A61K41/0057 , A61K39/0011 , A61K41/0052 , A61K47/61 , A61K47/6925 , A61K2039/55583 , A61K2039/6087 , A61N5/062 , B82Y5/00 , C12N5/0068 , C12N2533/30 , Y10S977/746 , Y10S977/918
Abstract: A method for constructing a compound of immunologically modified nanotubes and method for using the compound to deliver immunoadjuvants to tumor cells and to produce targeted, synergistic photophysical and immunological reactions for cancer treatment. To prepare the immunologically modified nanotubes, carbon nanotubes are dissolved in a solution of glycated chitosan, an immunostimulant, hence using glycated chitosan as a surfactant for rendering the aqueous solution of nanotubes stable. The compound can be used for treatment of cancer. The method includes steps of intratumorally administering immunologically modified nanotubes and administering laser irradiation of the target tumor. The nanotube serves as a carrier to deliver immunoadjuvants to the tumor cells and serves as a light-absorbing agent in a cell body of a tumor in a host. Upon laser irradiation of target tumor cells, immunologically modified nanotubes inside the tumor cells can produce spatially and temporally synchronized photothermal and immunological reactions for cancer treatment.
-
公开(公告)号：WO2012106251A2
公开(公告)日：2012-08-09
申请号：PCT/US2012/023152
申请日：2012-01-30
Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES , NATIONAL RESEARCH COUNCIL OF CANADA , CAMBRIDGE ENTERPRISE LIMITED , UNIVERSITY OF BRISTOL , KUBLER-KIELB, Joanna , SCHNEERSON, Rachel , ROBBINS, John, B. , GINZBERG, Ariel , LAGERGARD, Teresa , VINOGRADOV, Evguenii , MASKELL, Duncan , PRESTON, Andrew
Inventor： KUBLER-KIELB, Joanna , SCHNEERSON, Rachel , ROBBINS, John, B. , GINZBERG, Ariel , LAGERGARD, Teresa , VINOGRADOV, Evguenii , MASKELL, Duncan , PRESTON, Andrew
CPC classification number: A61K39/099 , A61K2039/55544 , A61K2039/6087 , A61K2039/627
Abstract: An immunogenic composition, comprising: (a) an immunogenic conjugate comprising the structure of: Pr - Sr - O - N = Kdo - OS (I) in which Pr represents carrier protein, Sr is an optional spacer moiety, Kdo is 3-deoxy-D- manno-octulosonic acid or a derivative thereof, and OS is an oligosaccharide or polysaccharide obtained from Bordetella bronchiseptica LPS, Bordetella pertussis LPS, or Bordetella parapertussis LPS; (b) diphtheria toxoid; and (c) tetanus toxoid.
Abstract translation: 免疫原性组合物，其包含：（a）包含以下结构的免疫原性缀合物：Pr-Sr-O-N = Kdo-OS（I），其中Pr表示载体蛋白，Sr是任选的间隔基，Kdo是3-脱氧 D-甘油 - 辛酸或其衍生物，OS是从支气管炎博德特氏菌LPS，百日咳博德特氏菌或副百日咳杆菌获得的寡糖或多糖; （b）白喉类毒素; 和（c）破伤风类毒素。
-
公开(公告)号：WO2012048333A1
公开(公告)日：2012-04-12
申请号：PCT/US2011/055689
申请日：2011-10-11
Applicant: R.P. SCHERER TECHNOLOGIES, LLC , TIAN, Wei , MCLAUGHLIN, Rosie
Inventor： TIAN, Wei , MCLAUGHLIN, Rosie
IPC: A61K9/00 , A61K39/145 , A61K47/36
CPC classification number: A61K9/006 , A61K9/0056 , A61K9/2095 , A61K39/12 , A61K39/145 , A61K2039/542 , A61K2039/55583 , A61K2039/57 , A61K2039/6087 , C12N7/00 , C12N2760/16134 , C12N2760/16151
Abstract: A fast-dissolving dosage form (FDDF) for the delivery of a vaccine is prepared using a formulation containing a starch, optionally, along with at least one additional matrix forming agent, preferably, a combination of gelatin and mannitol, wherein an immune response is induced in a patient in need thereof.
Abstract translation: 使用含有淀粉的制剂，任选地与至少一种另外的基质形成剂，优选明胶和甘露醇的组合，制备用于递送疫苗的快速溶解剂型（FDDF），其中免疫应答是 在有需要的患者中诱导。
-
-
-
-
-
-
-
-
-
Search Results
163
records
(took 0.029 seconds)
